SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high133.75 03/06/16
52 week low71.88 03/05/17
52 week change -20.38 (-17.72%)
4 week volume943,947 28/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Silence Therapeutics expands intellectual property estate

Silence Therapeutics has announced a significant expansion of its chemical modification patent estate, and might consider ...

Significant Expansion of Intellectual Property

RNS Number: 1978F Silence Therapeutics PLC 16 May 2017 Significant expansion of Intellectual Property (March to May 2017) 16 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a signific...

Silence Therapeutics schedules AGM

Silence Therapeutics has announced that the Annual General Meeting of the Company will be held on Friday 2 June. At 1:5...

Notice of AGM and Publication of Annual Report

RNS Number: 2075E Silence Therapeutics PLC 04 May 2017 Notice of AGM and publication of Annual Report 4 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its annual report an...

Silence Therapeutics Presents New Data

RNS Number: 9758D Silence Therapeutics PLC 03 May 2017 Silence presents new data 3 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has presented new pre-clinical data generate...

Additional Listing

RNS Number: 3542C Silence Therapeutics PLC 12 April 2017 Additional listing 12 April 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has issued and allotted 190,000 new ordinary share...

Grant of Share Options to Directors

RNS Number: 2721B Silence Therapeutics PLC 03 April 2017 Grant of share options to Directors 3 April 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has granted share options ("Optio...

Preliminary Results for the year to 31 Dec 2016

RNS Number: 6802A Silence Therapeutics PLC 28 March 2017 Preliminary results for the year to 31 December 2016 28 March 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces its preliminary r...

Fundamental DataMore

EPS-12.1
Dividend yield0 %

Equity Research (SLN)

edison investment research
Silence Therapeutics plc
13/04/2017
Edison Investment Research is terminating coverage on Silence Therapeutics (SLN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...

Latest discussion posts More

  • Re: Slow decline.

    Hi, Totally agree and I am not sure why apart from just general lack of interest. The attached might help cheer you up a ...
    27-Apr-2017
    tallyfox
  • Slow decline.

    Feels like death by a thousand cuts at the moment. What's it going to take to reverse this decline?
    27-Apr-2017
    rikid

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.30%
BP25%
TESCO20%
BARCLAYS18%
ROYAL BANK SCOT18%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN